for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Molecular Templates Inc

MTEM.OQ

Latest Trade

14.52USD

Change

0.02(+0.14%)

Volume

80,838

Today's Range

14.40

 - 

14.97

52 Week Range

4.51

 - 

16.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.50
Open
14.50
Volume
80,838
3M AVG Volume
7.94
Today's High
14.97
Today's Low
14.40
52 Week High
16.70
52 Week Low
4.51
Shares Out (MIL)
43.85
Market Cap (MIL)
635.89
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Molecular Templates Announces Pricing Of $50 Million Public Equity Offering

Molecular Templates Announces Proposed Public Equity Offering

Vertex And Molecular Templates Establish Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Molecular Templates Inc

Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

Contact Info

9301 Amberglen Blvd Ste 100

+1.512.8961555

https://mtem.com/

Executive Leadership

Harold E. Selick

Chairman of the Board

Jason Kim

President, Chief Operating Officer

Eric E. Poma

Chief Executive Officer, Chief Scientific Officer, Director

Adam D. Cutler

Chief Financial Officer, Treasurer, Secretary

Jonathan Lanfear

Director

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.740

2017

-2.110

2018

-1.020

2019(E)

-1.655
Price To Earnings (TTM)
--
Price To Sales (TTM)
30.63
Price To Book (MRQ)
10.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.71
LT Debt To Equity (MRQ)
5.67
Return on Investment (TTM)
-67.12
Return on Equity (TTM)
-49.10

Latest News

Latest News

BRIEF-Molecular Templates Reports Qtrly Loss Per Share ‍$0.26​

* MOLECULAR TEMPLATES, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Molecular Templates Closes $10 Million Debt Facility With Perceptive Advisors

* MOLECULAR TEMPLATES CLOSES $10 MILLION DEBT FACILITY WITH PERCEPTIVE ADVISORS Source text for Eikon: Further company coverage:

BRIEF-Molecular Templates Provides Corporate Update And Outlines 2018 Milestones

* MOLECULAR TEMPLATES PROVIDES CORPORATE UPDATE AND OUTLINES 2018 MILESTONES

BRIEF-Molecular Templates appoints Adam Cutler as CFO

* Molecular Templates strengthens management team with appointment of Adam Cutler as Chief Financial Officer

BRIEF-Molecular Templates Q3 loss per share $0.62

* Molecular Templates, Inc. Reports third quarter 2017 financial results

BRIEF-AbCheck and Molecular Templates collaborate to discover therapeutic oncology leads

* Says Abcheck will use Absieve discovery platform to deliver antibodies against biological targets selected by Molecular Templates

BRIEF-Molecular Templates files for sale of 11.6 mln shares of common stock by selling stockholders

* Molecular Templates Inc - files for sale of 11.6 million shares of common stock by selling stockholders - sec filing Source text: (http://bit.ly/2x68onC) Further company coverage:

BRIEF-Molecular Templates Inc files to say it raised $20 mln in equity financing

* Molecular Templates Inc files to say it raised $20 million in equity financing Source text (http://bit.ly/2i1OaYC) Further company coverage:

BRIEF-SHV Management Services reports 32.6 pct stake in Molecular Templates

* SHV Management Services reports 32.6 percent stake in molecular templates as of Aug 1 - SEC filing Source text: (http://bit.ly/2w4gAXS) Further company coverage:

BRIEF-Takeda Pharmaceutical Co reports 10.9 pct stake in Molecular Templates - SEC Filing

* Takeda Pharmaceutical Company reports 10.9 percent stake in Molecular Templates Inc as of August 1, 2017 - SEC Filing Source text: (http://bit.ly/2vTAtQL) Further company coverage:

BRIEF-Takeda Pharmaceutical and Molecular Templates announce research and licensing collaboration

* Takeda Pharmaceutical and molecular templates announce multi-target research and licensing collaboration to develop next-generation oncology therapies

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up